Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Announces Results For Phase 3 Trial Of Yervoy (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer


Thursday, 12 Sep 2013 04:25am EDT 

Bristol-Myers Squibb Company announced that it has reported results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel. The study's primary endpoint of overall survival (OS) did not reach statistical significance (HR = 0.85; 95% CI = 0.72-1.00; p = 0.053). However, anti-tumor activity was observed across some efficacy endpoints, including progression free-survival. These data will be presented at the 2013 European Cancer Congress in an oral session on September 28 (Abstract # 2850). 

Company Quote

48.62
0.11 +0.23%
11 Jul 2014